Lifecare Transitions to Euronext Oslo Børs as It Moves Closer to Market with Innovative Diabetes Technology

Lifecare Transitions to Euronext Oslo Børs as It Moves Closer to Market with Innovative Diabetes Technology

(IN BRIEF) Lifecare, a Norwegian medtech company developing implantable sensors for glucose and biomarker monitoring, has transitioned from Euronext Growth Oslo to the main Euronext Oslo Børs market. This marks a significant milestone for the company, with a market capitalization of NOK 317 million. Lifecare is focused on providing solutions for diabetes patients worldwide and is now preparing to bring its first product to market.

(PRESS RELEASE) OSLO, 22-Oct-2024 — /EuropaWire/ — Lifecare, a Norwegian medtech company specializing in miniaturized, implantable sensors for continuous monitoring of glucose and other biomarkers, has officially transitioned from Euronext Growth Oslo to the Euronext Oslo Børs. This move, completed on 22 October 2024, marks the second transfer between the two Oslo markets this year. Lifecare’s advanced technology is aimed particularly at aiding the more than 500 million people living with diabetes worldwide.

Headquartered in Bergen, Norway, Lifecare conducts its research and development in Germany, with facilities in Mainz and Reutlingen, and operates a chemistry lab in Bristol, UK. At the opening of its first day on the Oslo Børs, the company’s share price was NOK 20 per share, giving it a market capitalization of approximately NOK 317 million, based on the previous day’s closing price on Euronext Growth Oslo.

Joacim Holter, CEO of Lifecare, highlighted the significance of this step, stating, “This transition to the regulated Euronext Oslo Børs is a major milestone for Lifecare. The approval from Oslo Børs’ listing committee reflects the strength of our technology and progress. We are now ready to enter the main market with a clear focus on production and bringing our first product to market.”

About Lifecare

Lifecare ASA is a clinical stage medical sensor company developing technology for sensing and monitoring of various body analytes. Lifecare’s main focus is to bring the next generation of Continuous Glucose Monitoring (CGM) systems to market. Lifecare enables osmotic pressure as sensing principle, combined with the ability to manipulate Nano-granular Tunnelling Resistive sensors (NTR) on the sensor body for read-out of pressure variations. Lifecare’s sensor technology is referred to as “Sencell” and is suitable for identifying and monitoring the occurrence of a wide range of analytes and molecules in the human body and in pets.

About Euronext
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With nearly 1,900 listed issuers and around €6.3 trillion in market capitalisation as of end September 2024, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.

For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

Disclaimer
This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2024, Euronext N.V. – All rights reserved.

Media Contacts:

SOURCE: Euronext